568 related articles for article (PubMed ID: 34157213)
1. Prostate cancer in transgender women: what does a urologist need to know?
Bertoncelli Tanaka M; Sahota K; Burn J; Falconer A; Winkler M; Ahmed HU; Rashid TG;
BJU Int; 2022 Jan; 129(1):113-122. PubMed ID: 34157213
[TBL] [Abstract][Full Text] [Related]
2. Prostate-Specific Antigen Screening in Transgender Patients.
Nik-Ahd F; Jarjour A; Figueiredo J; Anger JT; Garcia M; Carroll PR; Cooperberg MR; Vidal AC; Freedland SJ
Eur Urol; 2023 Jan; 83(1):48-54. PubMed ID: 36344317
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer in transgender women.
Ingham MD; Lee RJ; MacDermed D; Olumi AF
Urol Oncol; 2018 Dec; 36(12):518-525. PubMed ID: 30322726
[TBL] [Abstract][Full Text] [Related]
4. Which U.S. States' Medicaid Programs Provide Coverage for Gender-Affirming Hormone Therapy and Gender-Affirming Genital Surgery for Transgender Patients?: A State-by-State Review, and a Study Detailing the Patient Experience to Confirm Coverage of Services.
Zaliznyak M; Jung EE; Bresee C; Garcia MM
J Sex Med; 2021 Feb; 18(2):410-422. PubMed ID: 33422448
[TBL] [Abstract][Full Text] [Related]
5. Fertility preservation for transgender adolescents and young adults: a systematic review.
Baram S; Myers SA; Yee S; Librach CL
Hum Reprod Update; 2019 Nov; 25(6):694-716. PubMed ID: 31633751
[TBL] [Abstract][Full Text] [Related]
6. Gender-affirming hormone therapy and the risk of sex hormone-dependent tumours in transgender individuals-A systematic review.
McFarlane T; Zajac JD; Cheung AS
Clin Endocrinol (Oxf); 2018 Dec; 89(6):700-711. PubMed ID: 30107028
[TBL] [Abstract][Full Text] [Related]
7. Prostate Cancer in Male-to-Female Transgender Individuals: Histopathologic Findings and Association With Gender-affirming Hormonal Therapy.
Baraban E; Ding CC; White M; Vohra P; Simko J; Boyle K; Guo C; Zhang M; Dobs A; Ketheeswaran S; Liang F; Epstein JI
Am J Surg Pathol; 2022 Dec; 46(12):1650-1658. PubMed ID: 36006769
[TBL] [Abstract][Full Text] [Related]
8. Gender Affirming Medical Treatment Desire and Treatment Motives in Binary and Non-Binary Transgender Individuals.
Kennis M; Duecker F; T'Sjoen G; Sack AT; Dewitte M
J Sex Med; 2022 Jul; 19(7):1173-1184. PubMed ID: 35418328
[TBL] [Abstract][Full Text] [Related]
9. Disparities in Prostate Cancer Screening for Transgender Women: An Analysis of the MarketScan Database.
Premo H; Gordee A; Lee HJ; Scales CD; Moul JW; Peterson A
Urology; 2023 Jun; 176():237-242. PubMed ID: 36972765
[TBL] [Abstract][Full Text] [Related]
10. Clinicians in the Veterans Health Administration initiate gender-affirming hormone therapy in concordance with clinical guideline recommendations.
Jasuja GK; Wolfe HL; Reisman JI; Vimalananda VG; Rao SR; Blosnich JR; Livingston NA; Shipherd JC
Front Endocrinol (Lausanne); 2024; 15():1086158. PubMed ID: 38800485
[TBL] [Abstract][Full Text] [Related]
11. The Effect of Gender-Affirming Hormone Therapy on the Risk of Subclinical Atherosclerosis in the Transgender Population: A Systematic Review.
Moreira Allgayer RMC; Borba GDS; Moraes RS; Ramos RB; Spritzer PM
Endocr Pract; 2023 Jun; 29(6):498-507. PubMed ID: 36603652
[TBL] [Abstract][Full Text] [Related]
12. Feminizing gender-affirming hormone therapy for the transgender and gender diverse population: An overview of treatment modality, monitoring, and risks.
Sudhakar D; Huang Z; Zietkowski M; Powell N; Fisher AR
Neurourol Urodyn; 2023 Jun; 42(5):903-920. PubMed ID: 36403287
[TBL] [Abstract][Full Text] [Related]
13. Routine Screening for Transgender and Gender Diverse Adults Taking Gender-Affirming Hormone Therapy: a Narrative Review.
Iwamoto SJ; Grimstad F; Irwig MS; Rothman MS
J Gen Intern Med; 2021 May; 36(5):1380-1389. PubMed ID: 33547576
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal Changes in Liver Enzyme Levels Among Transgender People Receiving Gender Affirming Hormone Therapy.
Hashemi L; Zhang Q; Getahun D; Jasuja GK; McCracken C; Pisegna J; Roblin D; Silverberg MJ; Tangpricha V; Vupputuri S; Goodman M
J Sex Med; 2021 Sep; 18(9):1662-1675. PubMed ID: 34366264
[TBL] [Abstract][Full Text] [Related]
15. Cancer screening and management in the transgender population: Review of literature and special considerations for gender affirmation surgery.
Panichella JC; Araya S; Nannapaneni S; Robinson SG; You S; Gubara SM; Gebreyesus MT; Webster T; Patel SA; Hamidian Jahromi A
World J Clin Oncol; 2023 Jul; 14(7):265-284. PubMed ID: 37583948
[TBL] [Abstract][Full Text] [Related]
16. Sperm quality in transgender women before or after gender affirming hormone therapy-A prospective cohort study.
Rodriguez-Wallberg KA; Häljestig J; Arver S; Johansson ALV; Lundberg FE
Andrology; 2021 Nov; 9(6):1773-1780. PubMed ID: 33683832
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of and factors associated with the use of gender-affirming hormonal therapy outside the reference regimen among transgender people in a community-led clinic in Metro Manila, Philippines: a retrospective cross-sectional study.
Eustaquio PC; Dela Cruz JDM; Araña Y; Rosos B; Rosadiño JDT; Pagtakhan RG; Regencia ZJG; Baja ES
BMJ Open; 2023 Sep; 13(9):e072252. PubMed ID: 37669846
[TBL] [Abstract][Full Text] [Related]
18. Gender-affirming hormone therapy induces specific DNA methylation changes in blood.
Shepherd R; Bretherton I; Pang K; Mansell T; Czajko A; Kim B; Vlahos A; Zajac JD; Saffery R; Cheung A; Novakovic B
Clin Epigenetics; 2022 Feb; 14(1):24. PubMed ID: 35177097
[TBL] [Abstract][Full Text] [Related]
19. Perceptions of Transgender and Nonbinary Persons Toward Breast and Cervical Cancer Development, Screening, and Potential Impact on Gender-Affirming Hormone Therapy.
Roznovjak D; Petroll AE; Lakatos AEB; Narayan R; Cortina CS
JCO Oncol Pract; 2023 May; 19(5):e794-e800. PubMed ID: 36800556
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
